|
|
 Previous Article | Table of Contents | Next Article 
The hematopoietic stem cell antigen, CD34, is not expressed on the
malignant cells in multiple myeloma
RA Vescio, CH Hong, J Cao, A Kim, GJ Schiller, AK Lichtenstein, RJ Berenson and JR Berenson
Division of Hematology/Oncology, DVA West Los Angeles, CA.
Autologous stem cell transplantation has become an important therapy in
multiple myeloma (MM). To develop adequate autograft purging methods, it is
necessary to determine whether antigens expressed on early hematopoietic
progenitors exist on malignant cells. The Ig heavy chain produced by the MM
cells shows evidence of prior somatic mutation without intraclonal
diversity. As a result, this sequence can be used as a specific marker to
detect all members of the malignant clone. The Ig heavy chain sequence
expressed by the MM cells was obtained in five patients with advanced
disease. Patient specific oligonucleotide primers were designed based on
the complementarity determining regions (CDR) of each MM Ig sequence and
used to amplify DNA by polymerase chain reaction for the detection of
malignant cells. A highly purified collection of CD34+ cells was obtained
after passage of the initial bone marrow cells through an immunoadsorption
column and fluorescence- activated cell sorting. Despite an assay
sensitivity of 1 tumor cell in 2,500 to 44,000 normal cells, none of the
CD34+ samples showed product with the myeloma-specific CDR primers.
Therefore, positive selection for cells bearing this antigen should yield a
tumor-free autograft capable of providing hematopoietic recovery after
myeloablative chemotherapy.
Volume 84,
Issue 10,
pp. 3283-3290,
11/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. M. Pilarski and A. R. Belch
Clonotypic Myeloma Cells Able to Xenograft Myeloma to Nonobese Diabetic Severe Combined Immunodeficient Mice Copurify with CD34+ Hematopoietic Progenitors
Clin. Cancer Res.,
October 1, 2002;
8(10):
3198 - 3204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Stewart, R. Vescio, G. Schiller, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadtmauer, S. Tarantolo, F. Sahebi, et al.
Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial
J. Clin. Oncol.,
September 1, 2001;
19(17):
3771 - 3779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Willems, O. Verhagen, C. Segeren, P. Veenhuizen, J. Guikema, E. Wiemer, L. Groothuis, T. B.-d. Jong, H. Kok, A. Bloem, et al.
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study
Blood,
July 1, 2000;
96(1):
63 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Pilarski, N. V. Giannakopoulos, A. J. Szczepek, A. M. Masellis, M. J. Mant, and A. R. Belch
In Multiple Myeloma, Circulating Hyperdiploid B Cells Have Clonotypic Immunoglobulin Heavy Chain Rearrangements and May Mediate Spread of Disease
Clin. Cancer Res.,
February 1, 2000;
6(2):
585 - 596.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Vescio, G. Schiller, A. K. Stewart, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadtmauer, S. Tarantolo, F. Sahebi, et al.
Multicenter Phase III Trial to Evaluate CD34+ Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma
Blood,
March 15, 1999;
93(6):
1858 - 1868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Szczepek, K. Seeberger, J. Wizniak, M. J. Mant, A. R. Belch, and L. M. Pilarski
A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction
Blood,
October 15, 1998;
92(8):
2844 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tricot, Y. Gazitt, T. Leemhuis, S. Jagannath, K.R. Desikan, D. Siegel, A. Fassas, S. Tindle, J. Nelson, C. Juttner, et al.
Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4489 - 4495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.V.B. Emmons, S. Doren, J. Zujewski, M. Cottler-Fox, C.S. Carter, K. Hines, J.A. O'Shaughnessy, S.F. Leitman, J.J. Greenblatt, K. Cowan, et al.
Retroviral Gene Transduction of Adult Peripheral Blood or Marrow-Derived CD34+ Cells for Six Hours Without Growth Factors or on Autologous Stroma Does Not Improve Marking Efficiency Assessed In Vivo
Blood,
June 1, 1997;
89(11):
4040 - 4046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Szczepek, P.L. Bergsagel, L. Axelsson, C. B. Brown, A. R. Belch, and L. M. Pilarski
CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene Rearrangements
Blood,
March 1, 1997;
89(5):
1824 - 1833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Demirer, C. Buckner, and W. Bensinger
Optimization of peripheral blood stem cell mobilization
Stem Cells,
January 1, 1996;
14(1):
106 - 116.
[Abstract]
|
|
|
|
|
